Brief: Theravance Biopharma's Lung Disease Drug Fails to Meet Main Goal of Study

Theravance Biopharma

05/01/2024 11:25

Jan 5 (Reuters) - Theravance Biopharma Inc  TBPH.O :
    * THERAVANCE BIOPHARMA ANNOUNCES RESULTS FROM THE PHASE 4
YUPELRI®
PIFR-2 STUDY IN PATIENTS WITH SEVERE TO VERY SEVERE CHRONIC
OBSTRUCTIVE PULMONARY DISEASE (COPD)
    * THERAVANCE BIOPHARMA INC: STUDY DID NOT SHOW A
STATISTICALLY
SIGNIFICANT DIFFERENCE BETWEEN YUPELRI AND SPIRIVA HANDIHALER ON
PRIMARY ENDPOINT
    * THERAVANCE BIOPHARMA INC: SIMILAR LUNG FUNCTION
IMPROVEMENT WAS
DEMONSTRATED IN BOTH ARMS OF STUDY
    * THERAVANCE BIOPHARMA INC: YUPELRI DEMONSTRATED SAFETY AND
TOLERABILITY CONSISTENT WITH ITS PROFILE IN PREVIOUS CLINICAL
STUDIES.

Source text for Eikon:  ID:nPn6bVY57a 
Further company coverage:  TBPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))